🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us today! Sept 2 7pm BST #BMJLeaderchat with @ElleryAltshule1 discussing his article on effective altruism Read it here for FREE ow.ly/BUaU50G2UwY Please join in to find out more & ask questions & share your views! Faculty of Medical Leadership and Management Institute for Healthcare Improvement (IHI) sanokondu #BlackLivesMatter The Q community

The concept is a very nice in essence and framed very aptly in the article😀 Will make for a very interesting discussion. Cannot wait to see & learn from the differing perspectives that others might take. See you there if you can make it! #Thursday #September2nd #BMJLeaderchat

I’m going to get boosted. Why? The efficacy is unclear, but it’s safe. It might protect my patients. It might keep me from getting benched when I’m needed most.🥊 It’s not a big deal, I get boosted every year. You look confused?? Oh, yeah… I’m talking about my flu shot.😝

A new FLORIDA study reports on the implementation of universal #ColorectalCancer genetic testing UF Health. While younger patients were more likely to be diagnosed with advanced disease, these patients had lower rates of genetic mutations. Read more: go.ufl.edu/5g402if

it would be interesting if someone could review all the articles published in The New York Times and CNN over the last 20 years, to determine what % of them ended up being wrong. cnn.com/2022/12/15/hea…

The P3 #CheckMate9DW study (1L ipilimumab + nivolumab) is positive! Data are particularly compelling considering control arm (mostly lenva whereas others went up against sora only) and significant crossover to 2L IO from the control arm. #HCC #ASCO2024

How long is too long to be performing CPR in patients who suffer in-hospital cardiac arrest? Every patient and situation is obviously different but it shouldn’t come as a surprise that beyond 30 minutes, things don’t look too good. 🎩 tip to the authors. eddyjoemd.com/foamed/

Oncology Brothers

Real world data on QTc prolongation with osimertinib Clinical Lung Cancer. 970 pts with #EGFR NSCLC & pre/post EKGs: 0.9% had G3 QTc prolongation (median onset d49) with no arrhythmic events; most had baseline QTc>450. Rechallenge better with dose reduction. clinical-lung-cancer.com/article/S1525-…

🔥Hot off the press🔥 Durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer 🔎updated overall survival from TOPAZ-1 phase 3 The Lancet Gastroenterology & Hepatology doi.org/10.1016/S2468-… 👉24-mo OS rate: 23·6% vs 11·5% ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation #livertwitter

📣 Guideline Watch 2024 is now available. Our annual collection, curated by NEJM Journal Watch physician-editors, includes 12 new and updated guideline summaries to help you stay informed in your practice. Download the collection: jwat.ch/4fvHwCu #guidelines

"There are many ways to improve the world, but their cost-effectiveness varies immensely. You can achieve a lot more if you rely on the best data on where to donate." Thank you Max Roser and Our World in Data for recognizing GiveWell's Top Charities as "concrete, real-life

Doxorubicin plus Trabectedin followed by Trabectedin maintenance for leiomyosarcoma shows OS benifit vs doxorubicin alone . Median OS Improved from 24 months to 33 months NEJM See the post progression therapy for both arms ( 36 % of control arm got Trabectedin on

🚨ADRIATIC Study: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell #LungCancer🫁 📉Overall Survival:Durvalumab: Median 55.9 months (95% CI, 37.3 to not reached) Placebo: Median 33.4 months (95% CI, 25.5 to 39.9) HR for death: 0.73 (P=0.01) 📉Progression-Free